Cargando…

304. Hepatocellular Carcinoma Occurs Frequently and Early After Treatment in HCV Genotype 3 Infected Persons Treated with DAA Regimens

BACKGROUND: Treatment of HCV with directly acting antiviral agents (DAAs) is associated with a significant reduction in cardiovascular, metabolic and cancer risk. However, there are conflicting data regarding the risk of hepatocellular carcinoma (HCC) after DAA treatment. Risk of HCC in HCV genotype...

Descripción completa

Detalles Bibliográficos
Autores principales:	Un Nabi Tayyab, Ghias, Rasool, Shafqat, Nasir, Bilal, Butt, Adeel A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809789/ http://dx.doi.org/10.1093/ofid/ofz360.377

Ejemplares similares

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
por: Tayyab, Ghias Un Nabi, et al.
Publicado: (2020)

Risk of Covid-19 infection during endoscopy: Efficacy of personal protective equipment (PPE) in protecting health professionals
por: Dilshad, Muhammad Akif, et al.
Publicado: (2021)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

Post-transplantation lymphoproliferative disorder with gastrointestinal involvement
por: Inayat, Faisal, et al.
Publicado: (2018)

DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
por: De Francesco, Maria Antonia, et al.
Publicado: (2022)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
por: Dawood, Reham M., et al.
Publicado: (2022)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
por: Chehl, Navdeep, et al.
Publicado: (2019)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs
por: Ponnuvel, Suresh, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
por: Sacks‐Davis, Rachel, et al.
Publicado: (2018)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
por: Márquez-Coello, Mercedes, et al.
Publicado: (2021)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
por: Farcomeni, Stefania, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bkg3rbo5ropjbantc9g5q4t0mn